PROZOLE-P DSR CAP is a widely prescribed fixed-dose combination of Pantoprazole (a proton pump inhibitor) and Domperidone (a dopamine D2 receptor antagonist with prokinetic and antiemetic properties). This delayed-release capsule is designed to manage a range of upper gastrointestinal disorders characterized by excessive acid production, slow gastric emptying, and nausea-related symptoms.

Pantoprazole, the primary acid-suppressing agent in the formulation, acts by irreversibly blocking the H+/K+ ATPase pump in gastric parietal cells, thereby inhibiting the final step in acid secretion. It ensures profound and long-lasting reduction in gastric acid output, which is critical in healing gastric and duodenal ulcers, and in the maintenance therapy for gastroesophageal reflux disease (GERD).

Domperidone complements the action of Pantoprazole by acting on the central and peripheral dopamine receptors. It enhances gastric emptying, strengthens lower esophageal sphincter tone, and alleviates symptoms such as bloating, nausea, early satiety, and vomiting. Its peripheral selectivity reduces the risk of neurological side effects commonly associated with other dopamine antagonists.

PROZOLE-P DSR CAP is especially effective in treating conditions such as GERD, non-ulcer dyspepsia, Zollinger-Ellison syndrome, erosive esophagitis, and gastritis. It is also useful for patients suffering from reflux-related chronic cough or laryngitis, by minimizing acid regurgitation and associated complications. Patients with functional dyspepsia who complain of upper abdominal discomfort, fullness, and belching experience significant symptomatic relief with this combination therapy.

The sustained-release and enteric-coated design of PROZOLE-P DSR CAP ensures that Pantoprazole is released only in the alkaline environment of the small intestine, maximizing its bioavailability while protecting it from gastric degradation. Domperidone is released promptly to provide quick relief from motility-related symptoms, offering both immediate and sustained action.

Dosage is typically once daily, administered before meals, which enhances patient compliance and improves therapeutic outcomes. It is generally well tolerated, with mild and infrequent side effects such as headache, dry mouth, abdominal cramps, and dizziness. However, long-term use should be monitored for risks like hypomagnesemia, vitamin B12 deficiency, or rebound acid hypersecretion.

Bluepill Express manufactures PROZOLE-P DSR CAP in advanced pharmaceutical facilities compliant with WHO-GMP, ISO, and other international regulatory certifications. Each capsule undergoes rigorous testing for dissolution profile, stability, uniformity, and pharmacological efficacy. Our product comes with all necessary documentation including COA, stability data, and regulatory support for semi-regulated and regulated markets.

With a strong global presence in over 140 countries including the UK, USA, Australia, Latin America, Africa, and Southeast Asia, Bluepill Express offers customized private labeling and third-party contract manufacturing for PROZOLE-P DSR CAP in various packaging formats. Whether clients require aluminum-aluminum blister packs, PVC blister packs, or bulk packing for hospital procurement, our infrastructure can accommodate diverse B2B needs.